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, 
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, Elena V. Boldyreva
b,c 
Metacetamol is a structural isomer of the widely used drug paracetamol and is being considered as a promising alternative 
to the latter because of its lower toxicity. Due to the importance of the well-known polymorphism ofparacetamol, an 
investigation of the polymorphism of metacetamol was successfully undertaken. A new polymorph of metacetamol has 
been discovered and extensively characterised using a variety of analytical techniques (IR- and Raman spectroscopy, UV-
visible optical spectroscopy, X-ray powder and single-crystal diffraction, TGA and DSC). A procedure for the reliable and 
reproducible preparation of the new polymorph is described. Its properties and crystal structure are compared with those 
of the previously known polymorph, as well as with those of paracetamol. 
Introduction 
Polymorphism in molecular crystals is an important area of research 
due to increasing interest within the pharmaceutical industry. A 
change in crystalline structure can cause properties to differ 
between polymorphs, and these  may have either beneficial or 
detrimental effects on a drug’s method of action1. Polymorphism is 
also an important issue for the protection of intellectual property 
2,3, and so for all of these reasons a complete description of all 
possible polymorphs is now recommended by Federal Food and 
Drug Administration (FDA) regulations4.  
Paracetamol provides an example of a popular and widely used 
Active Pharmaceutical Ingredient (API) that can exhibit 
polymorphism. Three polymorphs of this compound have been 
obtained at ambient pressure, and  all have different physical 
properties that are related to the differences in crystal structures5–
7. The monoclinic form I is the thermodynamically stable form at 
ambient pressure8, whereas the denser orthorhombic form II 
becomes thermodynamically stable at high pressure9–11. Two 
additional polymorphs were recently reported to form reversibly at 
very high (above 8 GPa) pressures12. Among the drawbacks of 
paracetamol for medical applications is its hepatotoxicity13–16. There 
is evidence that an isomeric compound, metacetamol (N-acetyl-
meta-aminophenol)17 (Scheme 1), is significantly less toxic18–21, 
although recent studies23  make this statement questionable 
reporting that metacetamol may also be hepatotoxic like 
paracetamol. Although various biological studies have been 
published for metacetamol22–24, nothing has yet been documented 
on the potential presence of polymorphic forms. Only one form has 
been described; its crystal structure has been solved17, but no 
studies of its vibrational spectra or thermal properties have been 
reported. 
The aim of this study was to investigate the polymorphism of 
metacetamol. In this work it was shown that another polymorph, 
form II, can be obtained from the melt in a reproducible manner. 
The bonding and stability of metacetamol form II was investigated 
thoroughly in relation to its crystal structure using a variety of 
relevant techniques, including thermal analysis and calorimetry, 
vibrational spectroscopy, UV-Visible spectroscopy, and X-ray 
diffraction. 
 
Scheme 1: Molecular structures of metacetamol (left) and paracetamol 
(right) containing the same characteristic functional groups 
Experimental 
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Materials 
Metacetamol was purchased from Sigma-Aldrich (form I) and was 
used after recrystallization from water. Depending on the 
procedure, purified single crystals or polycrystalline samples of 
form I were obtained. Form II was produced from recrystallized 
form I using procedures described later in the text. 
 
Characterisation 
X-ray powder diffraction. All polycrystalline samples were 
examined using a Bruker GADDS diffractometer: Cu Kα radiation (λ 
= 1.5418 Å), 5.0o ≤ 2Ө ≤ 46.0o, graphite monochromator, with an 
operating potential of 40 keV and a current of 40 mA. All data were 
obtained in reflection mode in a flat-plate configuration with a 
scanning time of 120 s per frame. In addition to laboratory 
experiments, X-ray powder diffraction data were recorded on 
Beamline I1125 at the Diamond Light Source using monochromatic 
radiation of wavelength 0.82562 Å from a sample of  finely ground 
form II contained in a 0.7 mm borosilicate-glass capillary. 
Single-crystal diffraction. Single, colourless plate-shaped crystals of 
metacetamol were obtained by slow cooling of a hot, aqueous, 
saturated solution of metacetamol capped with an immiscible layer 
of hexadecane. Thin, plate-like crystals formed at the interface of 
the aqueous and organic phases.  A suitable crystal (0.65 × 0.50 × 
0.05 mm3) was selected and mounted on a MITIGEN holder in 
Paratone oil on an Agilent Technologies SuperNova diffractometer. 
The crystal was maintained at T = 120.0 K during data collection. 
Using Olex2,26 the structure was solved with the ShelXS27 structure 
solution program, using the Direct Methods solution method. The 
model was refined with ShelXL27  using Least Squares minimization. 
Crystal Data. Chemical formula: C8H9NO2, Mr = 151.16, monoclinic, 
P21 (No. 4), a = 7.6202(8) Å, b = 19.010(3) Å, c = 10.1116(8) Å, α= 
90.388(8)°,  V = 1464.8(3) Å3, T = 120.0 K, Z = 8, Z' = 4, λ (CuKα) = 
1.5418 Å, 16412 reflections measured, 5281 unique (Rint = 0.0888) 
which were used in all calculations. The final wR2 was 0.3430 (all 
data) and R1 was 0.1078 (I > 2(I)).The poor quality of the very fragile 
and highly labile crystals accounts for the high values of Rint and R1. 
Differential Scanning Calorimetry (DSC). Calorimetric 
measurements were performed using a DSC-204 (Netzsch). Samples 
(9 mg of several small single crystals) were loaded into standard 
aluminium crucibles and covered with a lid, but not sealed. The 
heating rate was set to 6 K/min and the cooling rate was varied 
from 3 to 12 K/min, using liquid nitrogen as a cooling agent. 
Infrared Spectroscopy. FTIR ATR spectra were recorded using a 
DigiLab Excalibur 3100, Varian spectrometer equipped with a 
MIRacle ATR accessory in the range 600–4000 cm-1 with a 
resolution of 2 cm-1. A LinkamFTIR600 Stage, from Linkam Scientific 
Instruments Ltd, was used in conjunction with heater TMS 94 for 
the variable-temperature experiments. Heating was performed at 5 
K / min, with subsequent cooling at 2 K / min and (optional) 
retention at high (313 K) or ambient temperatures. A series of 
measurements was recorded either under an N2 atmosphere, or on 
air with different levels of relative humidity. Further details are 
described in the section on Results and Discussion. Harmonic 
frequencies for the IR spectrum of the gas-phase minimum 
structure of form I metacetamol were calculated using the Gaussian 
09 program35 with B3LYP/6-31+G(d,p) and MP2/6-31G(d) levels of 
theory (see Figure S.3.).  
Raman Spectroscopy. Raman spectra were recorded using a 
LabRAM HR 800 spectrometer from HORIBA JobinYvon with a CCD 
detector. For spectral excitation, the 488 nm line of an Ar+ laser was 
used with a beam size of ~1 μm on the surface of the sample and a 
power of ~8 mW. All data were collected using a Raman microscope 
in backscattering geometry. For the sample of form I, polarization 
was used along the mm and ll directions. Form II was examined 
without using polarized radiation as it could only be studied as a 
polycrystalline sample. 
UV-Vis Optical Spectroscopy. UV-VIS spectra were recorded using a 
Cary 60 UV-Vis spectrophotometer from Agilent Technologies, 
equipped with Agilent Cary 60 REMOTE DRA MVIDEO solid state 
auxiliary unit. All spectra were recorded in the range 200-800 nm 
with a resolution of 2 nm at a scan rate of 600nm/min. 
Chromatography. Chromatographic analysis of the samples was 
performed using an HPLC Agilent 1200 equipped with a Zorbax SB-
C18 (2.1x150mm, 3.5 µm) column used in conjunction with DAD 
(H2O-MeOH (30%-100%, 2-22')) and a GC-MS Agilent GC 6890 
equipped with a MSDetector 5973N. 
Chromatography studies (HPLC and GC-MS) were performed to 
check the purity of metacetamol form I samples after 
recrystallisation from water and for form II after its preparation as 
described below. For all samples the purities proved to be greater 
than 99%. 
Results and Discussion 
Preparation of form II 
Trial crystallisation studies from solution using common solvents 
(water, acetone, ethanol, ethyl acetate, THF, dioxane) produced 
only form I of metacetamol. From previous research it was known 
that form II of paracetamol could be produced under certain 
conditions from the melt 5 and so our studies on metacetamol also 
focused on the melt. A sample of form I was placed into a melting 
point apparatus (BÜCHI M-560) and heated to just above the 
reported melting point of 422 Kat a rate of 5 K/min until all traces of 
solid material had disappeared. The sample was then cooled down 
to 298 K at a rate of approximately 5 K/min. It was observed that 
the sample sub-cooled to give an optically transparent glass. On 
heating this glass a rate of 5 K/min, the glass was observed to 
crystallize at ~360 K to give a polycrystalline solid which 
subsequently melted at ~403 K. The difference of ~20 K in the 
melting points strongly suggested the existence of new polymorph 
that has significantly lower lattice energy. In order to produce larger 
quantities of this new form (henceforth denoted form II), a scaled-
up experiment was conducted using a Petri dish (diameter of 50 
mm, 10 mg of sample) and a hotplate. However, this method was 
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unsuccessful as the heating-cooling process was difficult to control, 
and invariably resulted in the formation of form I (identified by 
PXRD). Nevertheless, this experiment did confirm that the heating 
process did not result in thermal decomposition of the sample. In 
the next series of experiments a sample (100 mg) was heated in a 
sealed glass vial in an oil bath (up to 428 K at a rate of 2 K/min, 
followed by cooling to ambient temperature at an average rate of 
0.5 K/min). The heating of the sample was uniform, in order to 
minimise the likelihood of unwanted seeds of the undesirable form 
I, and contact with airborne contaminants was minimised. This 
method proved to be successful in producing form II as a 
polycrystalline powder, but it failed to produce single crystals. By 
using a programmable sublimation apparatus (BÜCHI B-585), form II 
was also successfully and reproducibly obtained, as heating and 
cooling rates were readily controlled (heating to 430 K at a 5 K/min 
and cooling at 0.4 K/min). Contact with air was also reduced using 
this apparatus as the experiment was performed under reduced 
pressure (16 mbar) in this device using a vacuum pump (BüCHI V-
700) with vacuum controller (BüCHI V-850). No sublimation was 
observed under these conditions.  Both methods produced a 
polycrystalline material. UV/Visible spectra of the samples of solid 
forms I and II recorded without grinding were essentially identical 
(Supp. Figure S1). 
Thermogravimetric analysis (TGA) of samples of both forms I and II 
showed negligible mass loss up to the melting point (Fig. 1,a), 
confirming that form II is not a solvate and that no significant 
thermal decomposition had occurred. 
Form I obtained by recrystallisation from aqueous solution 
contained about 1.4 % mass of solvent inclusions, as estimated 
from the presence of a small peak at  ~273 K in the DSC curves (Fig. 
1,b) combined with the TG data (Fig 1,a), which can be interpreted 
as melting of frozen inclusions of crystallisation liquor in the 
crystals. This is a very low value compared with many other organic 
crystals grown from solution 28.The presence of solvent inclusions is 
important to consider when discussing the stability of crystalline 
material on storage. It has been shown previously for paracetamol 
that these inclusions trigger the phase transformation of 
paracetamol II into paracetamol I on storage at ambient conditions 
and on heating29. On the contrary paracetamol II grown from the 
melt without solvent inclusions, melts without showing a 
polymorphic transition8.The DSC trace shown in Fig. 1,b shows that 
form I of metacetamol melts at approximately 420.5 K. On cooling 
the melt at 6 K/min, a substantial degree of sub-cooling was 
observed until an exothermic recrystallisation peak was observed 
over the range 363 - 340 K. On reheating, a melting peak was 
observed at 400 K, corresponding to the melting point of form II. 
These results are in agreement with the optical observations of 
samples in the melting-point apparatus, and indicate that form II 
crystallizes from the sub-cooled melt. 
 
 
Figure 1: a) TGA of recrystallised Form I (1) and Form II from the melt (2), 
showing the mass loss in Form I, accounted for by mother liquor inclusions 
and, b) Graph showing cyclic heating of recrystallised form I from the 1st 
heat cycle(1) which melts at 420 K, recrystallisation upon cooling (2), then 
the melting of new form II at much lower temperature (400 K) during the 
2nd heating cycle (3); cooling rate of 6K/min. Insert illustration represents a 
DSC signal from solvent inclusion (a small peak at 273K). 
X-ray powder diffraction studies 
Fig. 2 shows the diffraction patterns recorded for (1) a lightly 
ground sample of form I (2), a lightly ground sample of form II 
crystallised from the melt, and (3) a sample crystallised from the 
melt using the sublimation apparatus as described above with no 
grinding or mixing. 
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Figure 2: Powder diffraction patterns obtained for (1) a lightly ground 
sample of Form I, (2) Form II crystallized from the melt and then lightly 
ground, and (3) a sample of Form II obtained using the sublimation 
apparatus. (3). Plots are off-set along the y-axis for clarity. 
The diffraction pattern of the film produced using the sublimation 
apparatus was similar to that measured for the lightly ground 
sample obtained from the melt, and both patterns are clearly 
different from form I. Furthermore, these experiments demonstrate 
that form II can be prepared without contamination from form I.  
The higher background scattering observed in pattern (3) is caused 
by the presence of amorphous material that has not recrystallised. 
The observed differences in peak intensities between patterns (2) 
and (3) can be explained by preferred orientation associated with 
sample (3) 
Using the procedure developed for preparing pure samples of form-
II from the melt, it was possible to collect  X-ray powder diffraction 
data on Beamline I11 25 at the Diamond Light Source (see 
Experimental Section above). The diffraction pattern recorded at 
298 K is displayed in Fig. 3 and is in broad agreement with those 
obtained from the laboratory instrument. On account of the 
exceptionally high resolution available from this instrument, it was 
possible to index this pattern using the program DASH30 to a 
monoclinic cell (a = 7.80 Å, b = 19.12 Å , c = 10.16 Å, β = 90.43°, V = 
1515 Å3), with the most probable space group being P21 based on 
systematic absences.  This would therefore imply a value of Z’ = 4, 
based on the volume occupied per molecule.  Unfortunately, it was 
not possible to solve the structure using DASH, possibly because the 
pattern is dominated by only a few prominent peaks. 
 
Figure 3: Powder diffraction patterns obtained for Metacetamol Form II 
collected at 298 K on Beamline I11 using monochromatic radiation of 
wavelength 0.82562 Å at the Diamond Light Source. 
 
Single crystal X-ray diffraction study 
On account of the difficulties associated with solving the structure 
from X-ray powder diffraction data, attempts were made to grow 
single crystals of form II from a selection of common solvents. All of 
these attempts failed and so a different approach was adopted that 
was based on work described by Capes and Cameron in which the 
metastable orthorhombic form of paracetamol was obtained by the 
phenomenon of “contact-line crystallisation”31. A similar approach 
has also been used to grow single crystals of the highly metastable 
β-form of RDX32. In both cases, single crystals of the metastable 
forms grew at a solvent-air interface.   In the current study, we 
modified this procedure to create an interface between water and 
hexadecane –a high-boiling, water-immiscible liquid. An aqueous 
solution of metacetamol (saturated at ~70 °C) was heated to its 
boiling point in order to remove any possible seed crystals of form I.  
Whilst still hot, a layer of hexadecane was added to the vial, and on 
cooling to ambient temperature thin, plate-like crystals formed at 
the interface of the aqueous and organic phases.  Provided that the 
crystals of form II were retained in the crystallisation medium in a 
sealed vial, they appeared to be stable for a period of several days.  
However, if agitated in an open vial, they rapidly transformed to 
form I.The crystals were mechanically very fragile and rapidly 
transformed to form I unless they were handled very carefully.  The 
crystals also diffracted poorly and hence the quality of the 
diffraction data was not optimum.  Nevertheless, it proved possible 
to solve the structure in space group P21 using direct methods. The 
poor quality of the intensity data is quite obvious on inspection of a 
displacement ellipsoid plot: all ellipsoids are oriented in the same 
direction and all are quite significantly prolate. A strong similarity 
restraint (RIGU in ShelXL) was used to prevent several atoms from 
becoming non-positive definite during anisotropic refinement. The 
possibility of twinning was investigated, but we could not integrate 
the data assuming the crystal to be twinned as the reflections were 
too smeared out to identify a definitive second component. 
Integration using the option "follow significant sample movement" 
gave a significantly better refinement. 
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The calculated powder diffraction pattern  based on the model 
obtained from the single-crystal diffraction matched well the 
experimental patterns obtained for polycrystalline samples (Fig. 3), 
confirming that the bulk material obtained from the melt is the 
same form as the single crystals grown at the water/hexadecane 
interface.  
The crystal structure of metacetamol form II is remarkable (Fig. 4). 
In contrast to form I17 or to any of the polymorphs of paracetamol5–
7, the molecules are not linked as infinite chains, but instead form 
dimers via O-H...O hydrogen bonds between the phenolic -OH and 
the amide O=C groups. 
a) 
 
b) 
 
Fig.4. a) Representation of structural motifs in the structure of 
metacetamol II along a axis, b) along b axis. Hydrogen bonds are shown by 
dashed lines. 
Using graph-set notation to describe the H-bonded motifs in form I, 
metacetamol molecules form C22(6), C
2
2(14), C
4
4(20) chains and 
large R66(32) rings involving 6 molecules, while form II contains only 
R22(16)rings (formally R
2
2(16)>a>b and R
2
2(16)>c>d due to the 
inequivalence of pairs of dimers)‡. The dimers are not linked to 
other dimers by any hydrogen bonds, but instead pack to form a 
herring-bone arrangement along the a and c-axis with an angle of 
46° between the aromatic rings. The structure can also be described 
as zigzag motif of non-connected metacetamol molecules along the 
a-axis and wavy lines of dimers along b-axis. Unlike in form I, the N-
H bond of the amido-group is not involved in any significant 
interaction with neighboring molecules because of the formation of 
dimers.  
 
 
 
 
 
Table 1. Hydrogen bond geometries of metacetamol form I and II 
(Å, o) at 120 K 
Form D-H...A D...A 
Distance 
D-H...A 
Angle 
I O2-H2O...O1(i) 2.628(1) 165.98 
I N1-H1N...O2(ii) 2.953(1) 169.61 
II O21-H21...O2(iii) 2.69(1) 166.0 
II O1-H1...O22(iii) 2.68(1) 160.4 
II O31-H31...O12(iv) 2.67(1) 169.5 
II O11-H11...O32(iv) 2.67(1) 159.6 
Symmetry codes: (i) 2-x,1-y,-1/2+z; (ii) 3/2-x,-1/2+y,1/2+z; (iii) 
x,y,1+z; (iv) x,y,z. Atom numbering according to structure files from 
CCDC. Form I at 120 K is a Private communication to the CCDC 
(CCDC # 825236, S.L. Huth, T.L. Threlfall, M.B. Hursthouse, 
University of Southampton, Crystal Structure Report Archive , 542, 
2008; DOI: 10.3737/ecrystals.chem.soton.ac.uk/542). 
Hydrogen bonds are described in Table 1, showing that different 
types of H-bonds are present in two forms of metacetamol - N-H..O 
and O-H..O bonds in form I versus only O-H..O bonds in form II. 
Another peculiarity is that H-bonds in form II between and within 
dimers are slightly different (table 1). The formation of dimers via 
H-bonds became possible because metacetamol molecule has 
different stereochemical structure in the new form II than in 
previously reported polymorph I: the O-H and C=O groups are in a 
cis position in II but in a trans position in form I. Packing densities 
were calculated and compared for both structures.  They are 
practically equal, if compared at the same temperature. The volume 
per molecule of in Form II is 183 Å3 corresponding to a density of 
1.371 g/cm3 at 120 K.  Form I has a volume per molecule of 182 Å3, 
corresponding to a density of 1.378 g/cm3 at 120 K. The densities 
being practically the same, one can suppose that form II is 
metastable because of weaker directional intermolecular 
interactions, such as hydrogen bonds. It is well known that even 
denser forms of molecular crystals can be less stable, if denser 
packing actually results in weaker or fewer hydrogen bonds. Such 
an effect has been observed for the polymorphs of paracetamol, 
where the denser form is less stable at ambient pressure8,33. 
Polymorph II of metacetamol belongs to high Z’ crystal structures. 
Pseudosymmetry is frequently encountered in such cases and it 
seems to be also present here [for (010) layers slightly distorted p 
21/c 1 1 layer group symmetry with Z’=1]. Additionally, this 
pseudosymmetry can most probably be related to the crystal 
twinning. 
Vibrational spectroscopy 
Vibrational spectroscopy provided complementary insight into the 
properties of the hydrogen bonds in the new polymorph. Raman 
spectra recorded for both forms on cooling from 295 K to 5 K in 
steps of 20 K are shown in Figure 5.The main difference between 
the spectra of the two forms in the higher wavenumber ranges in 
the positions of the N-H stretching modes (3325 cm-1 for form I and 
3400 cm-1 for form II at 295 K). This is consistent with the crystal 
structure of form II in which the N-H groups are not involved in any 
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hydrogen bonds. Slight differences in the O-H..O vibrational modes 
were also observed - bands at 3104cm-1 and 3123 cm-1 for forms II 
and I, respectively. Differences in the low wavenumber range below 
1000 cm-1 can also be discerned, thereby providing an additional 
means of distinguishing the two forms34. The Raman spectra 
collected at variable temperature show that no phase transitions 
occur on cooling either Form I or Form II (Fig.5). 
a) 
 
b) 
 
c) 
 
Figure 5: a), b) polarized Raman spectra of Form I single crystals in two 
different directions (ll and mm respectively) and, c) Raman spectra of Form 
II without polarization (polycrystalline sample). 
Infrared spectroscopy was used to complement the Raman 
spectroscopic studies, in particular to follow the vibrations of the 
NH-groups. A large difference in the spectra in this region was 
observed for metacetamol I and II. A band at 3327 cm-1 (298 K) in 
the spectrum of form I (Figure 6 a,b) could be assigned to the N-H 
stretching mode, when compared to the gas phase spectra 
calculated in Gaussian0935 (DFT, B3LYP 6-31+G(d,p) and MP2, 6-
31G(d)) (see Supporting Information). A similar peak is present in 
the spectrum of form II (Figure 6 a,b), but both its position (3398 
cm-1) and intensity are changed, in agreement with the fact that the 
NH-group is no longer involved in a H-bond 
a)
 
b) 
 
Figure 6: a) IR spectra for Form I (1) and Form II (2); b) Expanded region 
showing the difference in N-H stretching modes between the two forms. 
The range between 1350-1550 cm-1 contains several modes that 
could be assigned to combined frequencies of δCNH with υPh and υCO 
by analogy with paracetamol36. Displacement of these bands also 
correlates with the change in vibration of the NH-group due to the 
absence of H-bonds. Another difference present in the "fingerprint 
region" of IR spectra (below 1000 cm-1) results in the disappearance 
of bands at 743 cm-1, 844 cm-1 and 918 cm-1 in the spectra of form  
II. Assignment of  OH-vibrations is very complicated and the origin 
of bands at 3269(w) cm
-1, 3209(w) cm
-1 and 3161(w) cm
-1 in the spectra 
of form  I  is not clear, bearing in mind that the O-H...O distances 
from the X-ray data are very close in both forms. Another 
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peculiarity for metacetamol II was discovered - the appearance of 
the band at 3952cm-1 (probably, a combination band), which was 
not observed in the spectra of metacetamol I, which can also be 
explained by the change in N-H group bonding. In general, with the 
exception of the NH-vibrations, the IR-spectra of both forms of 
metacetamol are very similar, thus providing  evidence that 
vibrations of other functional groups are not affected much by the 
change in molecular packing  
Transitions between metacetamol forms I and II 
In order to follow the transition from form I to the melt followed 
then by recrystallizsation to form II in situ, we used IR-spectroscopy 
and DSC. The characteristic peak associated with the N-H stretching 
mode observed at 3325 cm-1 in the infrared spectrum of form I was 
no longer visible in the spectrum of the melt (Fig.7). Instead, a 
broad absorption over the region 3000-3500 cm-1 was observed.  
When the experiment was carried out under dry N2, no 
crystallizsation of the melt was observed upon cooling or upon 
subsequent storage at 298 K for up to 12 hours. By contrast, when 
air was allowed to diffuse slowly into the container, crystallisation 
of melt into form II at 298 K occurred after approximately one hour 
and this resulted in the appearance of the N-H stretching mode at 
3400 cm-1, characteristic of form II (Fig. 7). 
 
Figure 7: Infra-red spectra showing the initial transformation from Form I 
(1) to Form II (3), through an intermediate melt stage (2), at which the 
characteristic N-H stretching mode disappeared. Plots are staggered along 
the y-axis for clarity. 
The transition to form II was also confirmed by measuring the 
melting temperature of the sample (399.5 K) with DSC. The effect of 
cooling rate was not studied during the IR experiment. The storage 
temperature apparently did not have any pronounced effect on the 
transition. On heating, form II to its melting point under dry N2, the 
melt did not crystallise (instead, it remained amorphous) after 
cooling over a period of at least a week (the maximum observation 
time). After the N2 was replaced by air, the crystallisation of the 
amorphous form to form II could be observed (Figure 8). 
 
Figure 8: IR-spectra, giving evidence of a slow transformation from an 
amorphous phase (1, 2) to Form II (3), seen over several hours, identified 
by the –NH peak which begins to form at ~ 3400 cm-1. Plots are staggered 
along the y-axis for clarity. 
During the variable-temperature IR-spectroscopy experiments, the 
sample partially sublimed and condensed onto the glass slide 
covering the cell. After the experiment, this cover slide was 
removed and the IR-spectrum of the condensed sample was 
recorded. The presence of both forms of metacetamol was 
confirmed by the IR-spectrum (Figure 9). 
a) 
 
b) 
 
Figure 9: a) IR spectrum recorded for the upper film which shows that both 
Form I and Form II have crystallised in the same environment, and b) 
expanded region, showing that peaks from both forms are present. 
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The sample was also inspected visually under the optical 
microscope, and this gave clear evidence that polycrystalline form II 
was present alongside crystals of form I (Figure 10). The behaviour 
and appearance of metacetamol form II is rather similar to that of 
the "elusive" paracetamol form III: both substances form drops with 
a large number of small crystallites radiating from the centre to 
borders of the drop34 
 
Figure 10: Optical image of the characteristic needles of Form I (circled in 
red), and polycrystalline Form II (circled in blue). 
The presence of air, and in particular moisture in the air, had a 
noticeable effect not only on the crystallisation of form II from the 
melt, but also on the transformation of form II to form I. This was 
demonstrated in an experiment in which a sample of form II was 
divided equally into three portions which were stored under 
different levels of relative humidity. Samples were monitored over 
a period of ~5 days, and X-ray powder diffraction patterns were 
measured at 24-hour intervals (Figure 11). To simulate humid 
conditions the sample contained in a diffractometer sample holder 
was placed under a jar (12 x 12 x 6 cm) alongside a vial containing 
~10 ml water. Ambient relative humidity of 50-60 % conditions 
were achieved by leaving the loaded sample holder exposed to the 
laboratory atmosphere. The third sample holder was placed inside a 
sealed desiccator with anhydrous calcium chloride used as the 
dessicant. The sample stored under dry conditions remained as 
pure form II over the study period, but the sample stored under 
humid conditions, to form I within 24 hours. Sample stored at 
ambient humidity also undergo transition to form I but slower. In 
this respect, it is worth noting that a transformation of paracetamol 
II to paracetamol I is also facilitated in the presence of water 
vapour, whereas dry samples can be preserved indefinitely long 8,37. 
a) 
 
b) 
 
Figure 11: a) XRPD of a sample under dry conditions, showing that Form II 
remains stable and does not undergo any transformation after 3 days, and 
b) XRPD showing a transformation from Form II to Form I after 1 day, 
triggered by the humidity. 
Conclusions 
A new polymorph (Form II) of metacetamol has been identified 
and characterised using a range of techniques.  Form II can be 
crystallised from the melt or at the interface of an aqueous-
organic layer.   
Form II exhibits a very different crystal packing from either 
Form I or any of the known polymorphs of paracetamol. This 
polymorph can be formed under certain conditions from the 
melt. It is highly unstable in the presence of even small 
amounts of water in the air, but can be preserved indefinitely 
long in dry atmosphere. In this respect, metacetamol II 
behaves similar to the orthorhombic paracetamol II. 
Metacetamol II melts at a significantly lower temperature than 
Form I and has a lower lattice energy despite having a very 
close density. This can be explained by consideration of its 
crystal structure in which metacetamol molecules form dimers 
linked by OH…O hydrogen bonds, whereas the N-H bonds of 
the amide groups are not involved in any hydrogen bonds.  
One would expect that Form II has a higher aqueous solubility 
than Form I and hence a higher bioavailability. Further studies 
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would be required to test this hypothesis, and given the 
propensity for Form II to transform to Form I in the presence 
of water, such studies are likely to be challenging.   
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The existence of a new polymorph of metacetamol together with its properties are reported for the first 
time. 
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